In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe as a short-term (12-week) treatment for reducing phlegm in chronic obstructive pulmonary disease (COPD), according to study findings ...

Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

Riociguat is generally safe and effective for PAH patients with coexisting cardiac and metabolic conditions, a trials ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...

The move will enable the country’s more than 100 million chronic pulmonary disease patients to access free annual check-ups.

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

Inhalers, nebulizers, and airway clearance devices are key to columnist Caroline Gainer's COPD management strategy.

A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.